Document Detail


Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.
MedLine Citation:
PMID:  6518295     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone. All women had previously received up to 4 modalities of endocrine therapy. Seventeen patients had also been treated with cytostatic drugs. Twenty-five percent of the 29 evaluable patients experienced objective tumor regression, lasting from 11 to more than 18 months. In 29% the disease was stabilized for 3 to more than 15 months. Toxicity was significant, necessitating drug withdrawal in 3 patients. One patient died within 3 weeks of therapy from multiple perforated gastric ulcers. Two patients developed herpes zoster within 4 weeks of treatment. Many side effects were minor and transient. However, treatment resulted in overt primary hypothyroidism in 25% of the evaluable patients and in a strongly increased need of acenocoumarin in all 3 patients on anticoagulant therapy.
Authors:
P F Bruning; J G Bonfrèr; E Engelsman; E Hamersma-vd Linden; M de Jong-Bakker; W Nooyen
Related Documents :
9010425 - Treatment of syringomyelia associated with arachnoid scarring caused by arachnoiditis o...
21091935 - Portal hypertension: diagnosis and management with particular reference to variceal hem...
11720675 - A treatment scale for axillary management in breast cancer.
23089445 - The use of bioabsorbable staple-line reinforcement performing stapled hemorrhoidopexy t...
18022495 - Application of the timi risk score in ed patients with cocaine-associated chest pain.
21251705 - Standard cardiopulmonary resuscitation versus active compression-decompression cardiopu...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  4     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  1984  
Date Detail:
Created Date:  1985-03-07     Completed Date:  1985-03-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  289-95     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aminoglutethimide / adverse effects*,  therapeutic use*
Breast Neoplasms / drug therapy*
Female
Humans
Hydrocortisone / therapeutic use
Menopause*
Middle Aged
Thyrotropin / blood
Chemical
Reg. No./Substance:
125-84-8/Aminoglutethimide; 50-23-7/Hydrocortisone; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manip...
Next Document:  The efficacy of bone scanning in the follow-up of patients with operable breast cancer.